Boothbay Fund Management LLC Trims Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Boothbay Fund Management LLC reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 52.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,518 shares of the medical equipment provider's stock after selling 6,167 shares during the period. Boothbay Fund Management LLC's holdings in Hologic were worth $398,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Brooklyn Investment Group lifted its position in Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock valued at $82,000 after acquiring an additional 145 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares during the last quarter. Trivant Custom Portfolio Group LLC grew its stake in Hologic by 2.1% in the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock worth $602,000 after buying an additional 169 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Hologic by 4.1% during the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock worth $343,000 after acquiring an additional 188 shares during the last quarter. Finally, Capital Investment Counsel Inc raised its position in Hologic by 3.6% during the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock valued at $413,000 after purchasing an additional 200 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Down 0.1 %

NASDAQ:HOLX traded down $0.05 during trading hours on Wednesday, hitting $53.06. The company's stock had a trading volume of 1,076,841 shares, compared to its average volume of 2,019,114. The stock has a fifty day moving average of $59.85 and a 200-day moving average of $68.78. The stock has a market capitalization of $11.91 billion, a P/E ratio of 16.75, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter last year, the business posted $1.03 EPS. The firm's quarterly revenue was down 1.2% compared to the same quarter last year. On average, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on HOLX shares. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. William Blair reiterated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Morgan Stanley decreased their price objective on Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a report on Monday. Stephens reiterated an "overweight" rating and issued a $84.00 price objective on shares of Hologic in a research report on Thursday, February 6th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research report on Friday, May 2nd. Twelve research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $79.85.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.